메뉴 건너뛰기
The Lancet Oncology
Volumn 14, Issue 10, 2013, Pages 910-911
Adjuvant bevacizumab: Positive data from a negative trial
Author keywords

[No Author keywords available]
Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;
EID: 84883055510     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70378-4     Document Type: Letter
Times cited : (2)
References (10)
  • 1
    • 84867042331 scopus 로고    scopus 로고
    • Progress against solid tumors in danger: the metastatic breast cancer example
    • Cortes J, Calvo E, Gonzalez-Martin A, et al. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol 2012, 30:3444-3447.
    • (2012) J Clin Oncol , vol.30 , pp. 3444-3447
    • Cortes, J.1    Calvo, E.2    Gonzalez-Martin, A.3
  • 2
    • 84883054546 scopus 로고    scopus 로고
    • First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    • (in press).
    • Miles D, Dieras V, Cortes J, Duenne AA, O'Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol (in press).
    • Ann Oncol
    • Miles, D.1    Dieras, V.2    Cortes, J.3    Duenne, A.A.4    O'Shaughnessy, J.5
  • 3
    • 84883050174 scopus 로고    scopus 로고
    • Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
    • published online Aug 7.
    • Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013, published online Aug 7. http://dx.doi.org/10.1016/S1470-2045(13)70335-8.
    • (2013) Lancet Oncol
    • Cameron, D.1    Brown, J.2    Dent, R.3
  • 4
    • 84856253589 scopus 로고    scopus 로고
    • Bevacizumab added to neoadjuvant chemotherapy for breast cancer
    • Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
    • (2012) N Engl J Med , vol.366 , pp. 310-320
    • Bear, H.D.1    Tang, G.2    Rastogi, P.3
  • 5
    • 84856291930 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
    • von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.
    • (2012) N Engl J Med , vol.366 , pp. 299-309
    • von Minckwitz, G.1    Eidtmann, H.2    Rezai, M.3
  • 6
    • 2542628099 scopus 로고    scopus 로고
    • Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
    • Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
    • (2004) Cancer Res , vol.64 , pp. 3731-3736
    • Tong, R.T.1    Boucher, Y.2    Kozin, S.V.3    Winkler, F.4    Hicklin, D.J.5    Jain, R.K.6
  • 7
    • 84870244259 scopus 로고    scopus 로고
    • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
    • de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012, 13:1225-1233.
    • (2012) Lancet Oncol , vol.13 , pp. 1225-1233
    • de Gramont, A.1    Van Cutsem, E.2    Schmoll, H.J.3
  • 8
    • 84875412193 scopus 로고    scopus 로고
    • Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    • Miles DW, de Haas SL, Dirix LY, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013, 108:1052-1060.
    • (2013) Br J Cancer , vol.108 , pp. 1052-1060
    • Miles, D.W.1    de Haas, S.L.2    Dirix, L.Y.3
  • 9
    • 84855161152 scopus 로고    scopus 로고
    • Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
    • Cortes J, Calvo V, Ramirez-Merino N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012, 23:1130-1137.
    • (2012) Ann Oncol , vol.23 , pp. 1130-1137
    • Cortes, J.1    Calvo, V.2    Ramirez-Merino, N.3
  • 10
    • 79959520764 scopus 로고    scopus 로고
    • Molecular stratification of triple-negative breast cancers
    • Perou CM Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(suppl 1):61-70.
    • (2011) Oncologist , vol.16 , Issue.SUPPL. 1 , pp. 61-70
    • Perou, C.M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.